Effect of Timolol on Refractive Outcomes in Eyes With Myopic Regression After LASIK: a Randomized Clinical Trial

Shahid Beheshti University of Medical Sciences

Status: Completed

Conditions: Myopic Regression

Treatments: Drug: Placebo; Drug: Timolol

Study type: Interventional

Funder types: Other

Identifiers

NCT01506635

8902

Details and patient eligibility

About

In this randomized controlled clinical trial, we compare the effects of timolol versus placebo for treatment of myopic regression after LASIK

Enrollment: 45 patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with myopic regression equal or more than 0.5 D with minimum age of 20 years,
• cylinder ≤ -1.00 D,
• corrected distance visual acuity (CDVA) of at least 20/40 were included.

Exclusion criteria

• Patients with a history of previous ocular surgery,
• keratoconus or any ectatic corneal disorder,
• keratoconus suspect by topography,
• preoperative corneal opacity,
• any corneal dystrophies,
• presence of pterygium,
• retinal disorders,
• collagen vascular disorders,
• diabetes mellitus,
• glaucoma,
• cataract,
• pregnancy,
• breast feeding
• systemic corticosteroid therapy were excluded.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

45 participants in 2 patient groups, including a placebo group

Control group

Placebo Comparator group

Description:

included patients who received artificial tear twice a day as control group.

Treatment:

Drug: Placebo

Timolol group

Experimental group

Description:

included the patients with myopic regression who received timolol 0.5% eye drop twice a day

Treatment:

Drug: Timolol